Clinical trial
VALENS: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT342, an AAV8-Delivered Gene Transfer Therapy in Crigler-Najjar Syndrome Subjects Aged 1 Year and Older
NCT03223194 is registered in ClinicalTrials.gov with Audentes Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- VALENS: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT342, an AAV8-Delivered Gene Transfer Therapy in Crigler-Najjar Syndrome Subjects Aged 1 Year and Older
- Lead sponsor
- Audentes Therapeutics
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- September 8, 2017
- Completion date
- February 11, 2021
- Enrollment
- 1 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.